SimianX AI LogoSimianX AI

प्राथमिक स्रोत रिकॉर्ड

निर्णायकटॉपलाइन परिणाम

Quince Therapeutics: LAM-001 के लिए PH-ILD में फेज़ 2b डेटा 2028 की पहली तिमाही में अपेक्षित

The acquisition of Orphai Therapeutics added LAM-001 to Quince’s pipeline. A 75-patient Phase 2b trial in PH-ILD is ongoing with topline results guided for Q1 2028. A separate Phase 2 BOS trial is fully enrolled with results expected Q1 2027.

मुख्य तथ्य

फाइल किया गया
30 जुल॰ 2026, 10:02 am
घटना
टॉपलाइन परिणाम
दिशा
तटस्थ
कंपनी
QNCXQuince Therapeutics, Inc.
संपत्ति
LAM-001
स्रोत
SEC 8-K
विश्वसनीयता
स्रोत सहित
फेज 2b नामांकन
75 रोगी
फेज 2a 6mwd वृद्धि
चिकित्सकीय रूप से प्रासंगिक
फेज 2a पीवीआर कमी
चिकित्सकीय रूप से प्रासंगिक
फेज 2a कार्यात्मक वर्ग सुधार
क्लास III से क्लास II

स्रोत का अंश

EX-99.4 3 d163930dex994.htm EX-99.4 EX-99.4 Exhibit 99.4 BUSINESS Our Company We are a clinical-stage biopharmaceutical company developing a novel disease modifying therapeutic to address the significant unmet medical need associated with pulmonary disorders with few, if any, treatment options available. On May 18, 2026, we completed the acquisition of Orphai Therapeutics, a clinical-stage biopharmaceutical company developing therapies to treat serious, underserved pulmonary disorders. The acquisition brought into our pipeline Orphai’s lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of conditions associated with dysfunctional mammalian target of rapamycin (“mTOR”) activity that cann

SEC 8-K